Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks

Journal of Pharmaceutical Sciences

Volumn 96, Issue 12, 2007, Pages 3293-3303

  De Matas, Marcel ^a   Shao, Qun ^a   Silkstone, Victoria Louise ^a   Chrystyn, Henry ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Aerosols; In vitro in vivo correlations (IVIVC); Lung bioavailability; Neural networks; Pulmonary drug delivery

Indexed keywords

SALBUTAMOL;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NEBULIZER; NORMAL HUMAN; URINARY EXCRETION;

EID: 36849091617     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20965     Document Type: Article

References (30)

1. FDA, Guidance for Industry: Immediate Release Solid Oral Dosage Forms: Scale-up and Post-approval Changes: Chemistry, manufacturing and Controls, in vitro Dissolution Testing, and in vivo Bioequivalence documentation1995.
2. FDA, Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in Vitro/in Vivo Correlations, 1997.
3. Silkstone VL, Dennis JH, Pieron CA, Chrystyn H. 2002. An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. J Aerosol Med 15:251-259.
4. Srichana T, Suedee R, Muanpanarai D, Tanmanee N. 2005. The study of in vitro-in vivo correlation: Pharmacokinetics and pharmacodynamics of salbutamol dry powder inhalers. J Pharm Sci 94:220-230.
5. Richardson CJ, Barlow DJ. 1996. Neural network computer simulations of medical aerosols. J Pharm Pharmacol 48:581-591.
6. Nazir J, Barlow DJ, Lawrence MJ, Richardson CJ, Shrubb I. 2002. Artificial neural network prediction of aerosol deposition in human lungs. Pharm Res 19:1130-1136.
7. Nazir J, Lawrence MJ, Shrubb I. 2005. Artificial neural network prediction of the patterns of deposition of polydisperse aerosols within human lungs. J Pharm Sci 94:1986-1997.
8. Bosco AP, Rhem RG, Dolovich MB. 2005. In vitro estimations of in vivo jet nebulizer efficiency using actual and simulated tidal breathing. J Aerosol Med 18:427-438.
9. Usmani OS, Biddiscombe MF, Barnes PJ. 2005. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Resp Crit Care Med 172:1497-1504.
10. Pritchard JN. 2001. The influence of lung deposition on clinical response. J Aerosol Med 14:S19-S26.
11. Vanto T, Hamalainen KM, Vahteristo M, Wille S, Nja F, Hyldebrandt N. 2004. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med 17:15-24.
12. Pilcer G, Sebti T, Amighi K. 2006. Formulation and characterisation of lipid-coated Tobramycin particles for dry powder inhalation. Pharm Res 23:931-940.
13. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. 2005. Influence of particle size and patient dosing technique on lung deposition of HFA-Bechlomethasone from a metered dose inhaler. J Aerosol Med 18:379-385.
14. Roth AP, Lange CF, Finlay WH. 2003. The effect of breathing pattern on nebulizer drug delivery. J Aerosol Med 16:325-339.
15. Cheng YS, Yazzie D, Gao J, Muggli D, Etter J, Rosenthal GJ. 2003. Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. J Aerosol Med 16:65-73.
16. Behzadi SS, Klocker J, Hüttlin H, Wolschann P, Viernstein H. 2005. Validation of fluid bed granulation utilizing artificial neural network. Int J Pharm 291:139-148.
17. Hussain AS, Shivanand P, Johnson RD. 1994. Application of neural computing in pharmaceutical product development: Computer aided formulation design. Drug Dev Ind Pharm 20:1739-1752.
18. Takayama K, Fujikawa M, Obata Y, Morishita M. 2003. Neural network based optimization of drug formulations. Adv Drug Delivery Rev 55:1217-1231.
19. Chen Y, McCall TW, Baichwal AR, Meyer MC. 1999. The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms. J Control Release 59:33-41.
20. Gobburu JVS, Chen EP. 1996. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. J Pharm Sci 85:505-510.
21. Mager DE, Shirey JD, Cox D, Fitzgerald DJ, Abernethy DR. 2005. Mapping the dose-effect relationship of orbifan from sparse data with an artificial neural network. J Pharm Sci 94:2475-2486.
22. Shao Q, Rowe RC, York P. 2006. Comparison of neurofuzzy logic and neural networks in modelling experimental data of an immediate release tablet formulation. Eur J Pharm Sci 28:394-404.
23. Bourquin J, Schmidli H, Hoogevest PV, Leuenberger H. 1997. Application of artificial neural networks (ANN) in the development of solid dosage forms. Pharm Dev Technol 2:111-121.
24. Dennis JH. 1995. Drug nebulizer design and performance: Breath enhanced jet vs. constant output jet vs. ultrasonic. J Aerosol Med 8:277-280.
25. Hindle M, Chrystyn H. 1992. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 34:311-315.
26. Zanen P, Go LT, Lammers JWJ. 1996. Optimal particle size for beta-2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51:977-980.
27. Stuart BO. 1973. Deposition of inhaled aerosols. Arch Intern Med 131:60-73.
28. Graham DR, Chamberlain MJ, Hutton I, King M, Morgan WK. 1990. Inhaled particle deposition and body habitus. Br J Ind Med 47:38-43.
29. Coates AL, Allen PD, MacNeish CF, Ho SL, Lands LC. 2001. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 119:1123-1130.
30. Rowe RC, Roberts RJ. 1998. Intelligent software for product formulation. London, UK: Taylor and Francis.